Key Takeaways
- Margin recovery underway, but input costs still weigh: EBITDA margin improved 130 bps QoQ to 11% in Crop Protection, while Pharma EBIT margin jumped to 9% from 3.6% in Q2, driven by product mix rationalization and cost initiatives, even as elevated raw material and energy costs persisted.
- Pharma volumes fell sharply, masked by mix shift: Pharma volumes declined ~17.5% YoY, yet revenue still grew as the portfolio shifted toward higher-value products; channel inventory destocking continues and a volume recovery is not expected until Q1–Q2 FY24.
- The capex cycle is entering its payoff phase: ₹550 crores of capex deployed over FY22–FY23 is now commissioning, with Panoli mechanically complete, a new fungicide plant starting revenue by early FY24, and an Animal Health multiyear contract coming on-stream in Q2 FY24.
- Management is promising a structurally different margin and return profile: New capex carries significantly higher gross margins, better EBITDA margins and better asset turns than the legacy portfolio; the company targets 21–22% EBITDA margins and 16–18% ROCE within two to three years.
- What to watch next quarter: Whether raw material price softening flows through to margins as inventory lags clear, the pace of Pharma channel inventory normalization, and any firm capex commitment for the next cycle after management's deliberate pause.
Margin & Input Cost Dynamics
- Sequential improvement despite headwinds: EBITDA margins improved 130 bps QoQ in Q3 as product mix optimization and cost-improvement initiatives partly offset the steep increase in raw materials, solvents and utilities; rising crude oil prices significantly impacted energy costs.
- Pharma EBIT swing: Pharma EBIT margin recovered to 9% in Q3 from 3.6% in Q2, with business excellence initiatives delivering cost reduction that absorbed some of the higher input cost burden.
- Crop Protection margin compression: Crop EBIT margin slipped to 11% (₹27 crores) from 13% (₹35 crores) in Q2, on the back of higher input costs for raw materials, solvents and energy.
- Raw material softening is real but lagged: Prices of key raw materials have started declining from peaks seen in 2021 and 2022; only a marginal benefit was captured this quarter due to inventory on-hand, with the full effect expected from Q4 onwards and into Q1 FY24.
- Personnel costs front-loaded: Fixed costs and personnel costs increased because of advance recruitment for new plants being commissioned in the next couple of quarters; employees were brought in early for training, creating a lag before commissioning and revenue accrual.
- Product mix rationalization is the structural margin lever: The company has spent several quarters optimizing the product mix; new products and new capex carry much higher gross margins, better EBITDA margins and better asset turns than the legacy portfolio.
Hiremath: "The margin profile will undergo significant change in the next three to four years compared to where we are today."
Volume & Channel Inventory
- Pharma volume de-growth was severe: Pharma volumes declined approximately 17.5% in Q3, yet value still increased due to a product mix shift toward more high-value products.
- Crop Protection volumes grew strongly: Crop Protection delivered about 20% volume growth; value growth lagged volume growth in the quarter due to product mix, but on a nine-month basis both volume and value grew for Crop.
- Pharma channel destocking still underway: Pharma channel inventories have come down over the last couple of quarters but are still present; it will take one or two more quarters for channel inventory to normalize and build back up.
- Crop channel inventories building: Some channel inventory build-up has occurred in Crop Protection; one to two quarters of inventory demand correction is expected. The company is de-risking via product mix optimization and a large product basket.
- Pharma generic pricing under pressure: Prices in the generic Pharma market have come down, with the US market severely affected; the CDMO side is more stable than the generic side. Crop Protection pricing has been more or less stable.
Capex Cycle & New Capacity
- ₹550 crores deployed, now commissioning: The capex program spanning FY22 and FY23 is expected to drive increased top-line over the next two to three years, with peak utilization taking two to three years from commissioning.
- Panoli plant mechanically complete: Mechanical completion has been achieved and commissioning has started; production is expected from Q1 FY24 with revenue accrual subsequently.
- New fungicide plant on track: Planning to complete plant commissioning by end of FY23 and start revenue accrual in early FY24.
- Animal Health multiyear contract: A multipurpose asset with a multiyear, multi-product contract is expected to come on-stream in Q2 FY24, with commercial supply starting in H2 FY25 following an 11–12 month validation period after commissioning.
- Capex pause for the next cycle: Priority is to complete residual capex, commission plants, optimize product mix, and wait-and-watch the global environment; debottlenecking of current assets will improve asset turns. Management will wait a quarter or so before finalizing large capex.
- Contract-to-capex timeline: Typically 18 to 24 months after acquiring a contract, depending on project size, covering process development, piloting and then capex.
Hiremath: "We're going to wait for a quarter or so before we finalize our large capex."
CDMO Pipeline & Portfolio Shift
- NCE pipeline deepening: Several new projects in NCE development across both Pharma and Crop, developing products on patent and under registration, and on the animal health side; several projects are moving into clinical Phase-II and Phase-III with good traction on the customer side.
- Pharma CDMO commercialization timeline: Several customers in the Phase-III segment are expected to move toward commercialization in 2024 and 2025.
- Gross margin transformation ahead: CDMO business gross margins are significantly better than generics margins; the portfolio is undergoing a dramatic change over the next few years with optimization and replacement of older molecules with higher-margin products. Over the next four to five years, gross margins will be materially better on a blended basis than in the past, per an analyst's math affirmed by management.
- Blue Chip customer acquisition: Significant traction with new Blue Chip customer acquisitions in both Crop and Pharma; RFPs and projects have already started, with many audits and customer visits taking place.
- Consolidated supplier advantage: Customers are looking at a consolidated supplier base; new entrants with capacity do not have guaranteed business without relationships and a track record with the FDA.
Hiremath: "I think the future is very bright. There are several new projects in both NCE both Pharma and in Crop where we're developing products, which are on patent and under for registration and on the animal side as well. So the future will look very different from the last 10 years..."
ESG & Operational Initiatives
- Zero effluent progress: The Pharma business in Bangalore is already zero effluent. New projects in Crop and Pharma are all zero effluent with recycling. Water consumption per kg and waste generation are decreasing year-on-year.
- Crop waste reduction program: A major waste reduction program has been implemented on the existing Crop side over the last 9–10 months; effluent going to designated authorities is reducing quarter-on-quarter.
- Solar power agreement signed: An agreement with a solar vendor for 12 MW power for Maharashtra units has been signed; power supply is expected to start this month (Q3 FY23).
- ESG roadmap underway: The company is working with an international partner to map baseline practices and define a roadmap for decarbonization, waste and water management, with very strict targets over the next couple of years to reduce carbon footprint and recycle waste.
- Business excellence delivering: An in-depth capital efficiency program has started yielding positive results, partly absorbing the impact of higher input costs.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin target | Reach 21–22% on a blended basis | Next couple of years |
| ROCE target | Grow to 16–18% | Next couple of years |
| Pharma volume recovery | Volumes to start coming back | Q1–Q2 FY24 |
| Pre-2022 margin recovery | Start moving back to steady-state margins | From Q2 FY24 onwards |
| Panoli plant production | Production and revenue accrual begin | Q1 FY24 |
| New fungicide plant revenue | Commissioning complete, revenue accrual starts | Early FY24 |
| Animal Health plant commissioning | Plant commissioning complete | Q2 FY24 |
| Animal Health commercial supply | Commercial supply starts after 11–12 month validation | H2 FY25 |
| Capex peak utilization | Peak optimization of ₹550 Cr capex deployed | 2–3 years |
| Gross margin transformation | Materially better blended gross margins vs past | 4–5 years |
| FY24 guidance | No guidance given; waiting and watching macro uncertainties | Revisit at end of Q4 FY23 |
| Next large capex decision | Wait a quarter or so before finalizing | ~Q4 FY23 / Q1 FY24 |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue | ₹540 cr, vs ₹559 cr in Q2 FY23 |
| 9M FY23 revenue | ₹1,478 cr, vs ₹1,440 cr in 9M FY22 |
| EBITDA margin improvement | 130 bps QoQ improvement vs Q2 FY23 |
| Pharma revenue | ₹292 cr, vs ₹290 cr in Q2 FY23 |
| Pharma EBIT margin | 9%, vs 3.6% in Q2 FY23 |
| Pharma 9M FY23 revenue | ₹806 cr, vs ₹822 cr in 9M FY22 |
| Crop Protection revenue | ₹248 cr, vs ₹269 cr in Q2 FY23 |
| Crop Protection EBIT margin | 11%, vs 13% in Q2 FY23 |
| Crop Protection 9M FY23 revenue | ₹671 cr, vs ₹619 cr in 9M FY22 |
| Crop Protection volume growth | ~20% YoY |
| Pharma volume de-growth | ~17.5% YoY |
| Total debt | ₹800 cr, long-term ₹500 cr, short-term ₹300 cr |
| Cost of funding | 8.5% long-term, 7% short-term |
| Capacity utilization | 80% to 85% across sites |
| FY23 capex | ~₹300 cr, ~₹200 cr spent in 9M, ~₹100 cr to be spent in Q4 |
| Asset turns at peak utilization | 1.4x to 1.5x |
| Interim dividend | 30% |
| Pharma CDMO commercial molecules | 5 molecules currently in commercial phase |
| Animal Health plant validation period | 11 to 12 months from commissioning in Q2 FY24 |
| Solar power agreement | 12 MW for Maharashtra units, payback under 1 year |